Catalyst
Slingshot members are tracking this event:
Zymeworks's (ZYME) Zanidatamab (ZW25) HER2-positive Gastroesophageal Adenocarcinoma Phase 2 data to be presented at ESMO September 16, 2021
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ZYME | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 16, 2021
Occurred Source:
https://ir.zymeworks.com/news-releases/news-release-details/zanidatamab-phase-2-clinical-trial-demonstrates-promising
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Zanidatamab, Her2-positive Gastroesophageal Adenocarcinoma
